PDL BIOPHARMA INC's ticker is and the CUSIP is 69329YAF1. A total of 18 filers reported holding PDL BIOPHARMA INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $7,296,000 | +47.7% | 7,287,000 | +47.5% | 0.11% | +54.1% |
| Q3 2017 | $4,940,000 | -1.0% | 4,940,000 | -1.2% | 0.07% | -9.8% |
| Q2 2017 | $4,989,000 | -45.5% | 5,000,000 | -45.7% | 0.08% | -38.3% |
| Q1 2017 | $9,157,000 | +43.8% | 9,200,000 | +41.5% | 0.13% | +41.5% |
| Q4 2016 | $6,369,000 | -41.3% | 6,500,000 | -41.4% | 0.09% | -33.3% |
| Q3 2016 | $10,842,000 | -10.8% | 11,091,000 | -13.3% | 0.14% | -35.6% |
| Q2 2016 | $12,160,000 | +20.3% | 12,791,000 | +15.0% | 0.22% | +20.3% |
| Q1 2016 | $10,106,000 | +53.2% | 11,121,000 | +34.1% | 0.18% | +109.2% |
| Q4 2015 | $6,595,000 | -47.0% | 8,296,000 | -41.3% | 0.09% | -46.6% |
| Q3 2015 | $12,446,000 | -7.4% | 14,138,000 | 0.0% | 0.16% | +4.5% |
| Q2 2015 | $13,444,000 | +38.4% | 14,138,000 | +39.5% | 0.16% | +52.9% |
| Q1 2015 | $9,715,000 | – | 10,138,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Radcliffe Capital Management, L.P. | 19,703,000 | $19,738,000 | 2.83% |
| ASCEND CAPITAL, LLC | 43,840,000 | $43,727,000 | 1.65% |
| ZAZOVE ASSOCIATES LLC | 2,080,000 | $2,085,000 | 0.11% |
| Verition Fund Management LLC | 1,000,000 | $1,004,000 | 0.08% |
| OAKTREE CAPITAL MANAGEMENT LP | 4,940,000 | $4,940,000 | 0.07% |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | 3,420,000 | $3,424,000 | 0.05% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 37,800,000 | $37,702,476,000 | 0.03% |
| Sterneck Capital Management, LLC | 18,000 | $18,000 | 0.01% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 235,000 | $212,000 | 0.00% |
| INVESTMENT CENTERS OF AMERICA INC | 50,000 | $50,000 | 0.00% |